170 related articles for article (PubMed ID: 35029705)
1. PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.
Huang J; Xiao J; Peng Z; Shao P; Sun M; Long Y; Wang X; Shen M; Kang D; Yang Y; Peng X; Wang W; Xie P; Shao T; Zhao J; Wu R
Psychopharmacology (Berl); 2022 Jan; 239(1):83-91. PubMed ID: 35029705
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways.
Huang P; Ran J; Zhu W; Dai W; Tang Y; Lian P; Huang X; Li R
FASEB J; 2024 Feb; 38(4):e23464. PubMed ID: 38358343
[TBL] [Abstract][Full Text] [Related]
4. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
[TBL] [Abstract][Full Text] [Related]
5. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
6. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
[TBL] [Abstract][Full Text] [Related]
7. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.
Jeong HJ; Lee HS; Kim KS; Kim YK; Yoon D; Park SW
J Lipid Res; 2008 Feb; 49(2):399-409. PubMed ID: 17921436
[TBL] [Abstract][Full Text] [Related]
8. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey.
Jensen KK; Tadin-Strapps M; Wang SP; Hubert J; Kan Y; Ma Y; McLaren DG; Previs SF; Herath KB; Mahsut A; Liaw A; Wang S; Stout SJ; Keohan C; Forrest G; Coelho D; Yendluri S; Williams S; Koser M; Bartz S; Akinsanya KO; Pinto S
J Lipid Res; 2016 Dec; 57(12):2150-2162. PubMed ID: 27707816
[TBL] [Abstract][Full Text] [Related]
10. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
11. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
[TBL] [Abstract][Full Text] [Related]
12. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
13. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.
Park SW; Moon YA; Horton JD
J Biol Chem; 2004 Nov; 279(48):50630-8. PubMed ID: 15385538
[TBL] [Abstract][Full Text] [Related]
14. High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats.
Ou-Yang YN; Deng FF; Wang YJ; Chen M; Yang PF; Yang Z; Tian Z
Biochimie; 2024 Jan; 216():34-45. PubMed ID: 37844755
[TBL] [Abstract][Full Text] [Related]
15. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.
Jia YJ; Zhang Y; Liu J; Guo YL; Xu RX; Li JJ
Chin J Integr Med; 2016 Feb; 22(2):96-100. PubMed ID: 24993334
[TBL] [Abstract][Full Text] [Related]
17. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
18. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
